Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. 1987

F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier

We recently reported the isolation of a new retrovirus, termed human immunodeficiency virus type 2 (HIV-2), from two West African patients with the acquired immunodeficiency syndrome (AIDS). This virus is related to but distinct from the well-characterized AIDS retrovirus, human immunodeficiency virus type 1 (HIV-1). We report here evidence of infection with HIV-2 in 30 patients, almost all from West Africa. Seventeen of them had a clinical syndrome indistinguishable from AIDS (7 of these 17 died). Others had either the AIDS-related complex or no HIV-related symptoms. All patients had serum antibodies reacting with HIV-2 in an indirect immunofluorescence assay. All serum tested contained antibodies reacting with the envelope glycoprotein of the virus in an immunoprecipitation assay. Cross-reactivity of serum antibodies with HIV-1 was detected in a minority of patients and varied according to the assay used. Retroviral isolates were obtained from the blood lymphocytes of 11 patients and were all identified as HIV-2 by nucleic acid hybridization; none hybridized with an HIV-1 probe. These findings indicate that some cases of AIDS in West Africa may be caused by HIV-2, but the extent of the spread of this virus and its clinical correlates will require careful epidemiologic investigation.

UI MeSH Term Description Entries
D008297 Male Males
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D005260 Female Females
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000354 Africa, Western The geographical area of Africa comprising BENIN; BURKINA FASO; CABO VERDE, COTE D'IVOIRE (formerly Ivory Coast); GAMBIA; GHANA; GUINEA; GUINEA-BISSAU; LIBERIA; MALI; MAURITANIA; NIGER; NIGERIA; SENEGAL; SIERRA LEONE; and TOGO. Africa, West,West Africa,Western Africa
D000386 AIDS-Related Complex A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS. ARC,Lymphadenopathy Syndrome,AIDS Related Complex,Complex, AIDS-Related,Lymphadenopathy Syndromes,Syndrome, Lymphadenopathy,Syndromes, Lymphadenopathy
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated

Related Publications

F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
January 1988, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
January 1995, International journal of STD & AIDS,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
May 2014, Enfermedades infecciosas y microbiologia clinica,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
April 1989, Lancet (London, England),
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
October 1989, World Health Organization AIDS technical bulletin,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
May 1994, Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
May 1987, Science (New York, N.Y.),
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
December 1999, Acta medica portuguesa,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
March 1996, Ugeskrift for laeger,
F Clavel, and K Mansinho, and S Chamaret, and D Guetard, and V Favier, and J Nina, and M O Santos-Ferreira, and J L Champalimaud, and L Montagnier
September 1993, The Journal of infectious diseases,
Copied contents to your clipboard!